Difference between revisions of "Renal cell carcinoma - historical"
Warner-admin (talk | contribs) m (Text replacement - "[[Medroxyprogesterone acetate" to "[[Medroxyprogesterone") |
Warner-admin (talk | contribs) m (Text replacement - "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy" to "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Comparative Efficacy") |
||
Line 20: | Line 20: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)03544-2/fulltext Medical Research Council Renal Cancer Collaborators 1999 (MRC RE01)] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)03544-2/fulltext Medical Research Council Renal Cancer Collaborators 1999 (MRC RE01)] | ||
Line 45: | Line 45: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.9.2859 Pyrhönen et al. 1999] | |[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.9.2859 Pyrhönen et al. 1999] | ||
Line 163: | Line 163: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5029 Ravaud et al. 2008] | |[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5029 Ravaud et al. 2008] |
Revision as of 03:24, 10 May 2019
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main RCC page for current regimens.
9 regimens on this page
9 variants on this page
|
Metastatic disease, first-line
Medroxyprogesterone monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Medical Research Council Renal Cancer Collaborators 1999 (MRC RE01) | Phase III (C) | IFN alfa-2a | Seems to have inferior OS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Hormonotherapy
References
- Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999 Jan 2;353(9146):14-7. link to original article contans protocol PubMed
Vinblastine monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Pyrhönen et al. 1999 | Phase III (C) | Vinblastine & IFN alfa-2a | Inferior OS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
References
- Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999 Sep;17(9):2859-67. link to original article PubMed
Metastatic disease, second-line
FC, then allo HSCT
back to top |
FC: Fludarabine & Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Childs et al. 2000 | Non-randomized, <20 pts |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days -5 to -1
- Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -7 & -6
Immunotherapy
- Allogeneic stem cells transfused on day 0
One course
References
- Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8. link to original article contains verified protocol PubMed
Interferon alfa-2a monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Aass et al. 2005 (EORTC 30951) | Phase III (C) | IFN alfa-2a & Isotretinoin | Seems to have inferior OS |
Immunotherapy
References
- EORTC 30951: Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8. link to original article PubMed
Interferon alfa-2a & Isotretinoin
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Aass et al. 2005 (EORTC 30951) | Phase III (E) | IFN alfa-2a | Seems to have superior OS |
Immunotherapy
References
- EORTC 30951: Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8. link to original article PubMed
Interferon alfa-2c monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
De Mulder et al. 1995 (EORTC 30885) | Phase III (C) | IFN alfa-2c & IFN gamma | Seems not superior |
Immunotherapy
References
- EORTC 30885: De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R; The EORTC Genitourinary Group. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. Br J Cancer. 1995 Feb;71(2):371-5. link to original article link to PMC article PubMed
Megestrol monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Ravaud et al. 2008 | Phase III (C) | Lapatinib | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm. Kelley & Baker 1961 examined a variety of progestins and is included for historic interest.
Hormonotherapy
References
- Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol. 2008 May 10;26(14):2285-91. link to original article PubMed